Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech has initiated a first-in-human phase 1 clinical trial in mainland China for HLX37, a recombinant humanised bispecific antibody that simultaneously targets PD-L1 and VEGF, in patients with advanced or metastatic solid tumours. The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary efficacy across monotherapy and combination-therapy arms, seeking to determine the maximum tolerated dose and a recommended phase 2 dose, while also exploring biomarkers and key efficacy measures such as response rates and survival outcomes. HLX37 is designed to combine immune checkpoint blockade with anti-angiogenesis in a single molecule, potentially delivering synergistic antitumour effects and reducing resistance compared with separate PD-L1 and VEGF agents, positioning Henlius to compete in the nascent but promising global market for PD-1/PD-L1 and VEGF bispecific antibodies, where the first product was only approved in 2024 and sales remain at an early stage.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on the independent research and development of innovative biologic drugs, particularly monoclonal and bispecific antibodies for oncology indications. Leveraging its expertise in immuno-oncology and targeted therapies, the company is expanding its pipeline in solid tumour treatments, aiming to capture opportunities in fast-growing segments such as PD-1/PD-L1 and VEGF pathway inhibitors.
Average Trading Volume: 1,152,404
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.66B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.